Drug Search Results

Perifosine

Alternative Names: perifosine
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Akt Inhibitor,PI3K Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AEterna Zentaris
Company Location: MONTREAL A8 H3B 3V2
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Perifosine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Colorectal Cancer|Multiple Myeloma

Phase 2: Prostate Cancer|Waldenstrom Macroglobulinemia|Adenocarcinoma|Pancreatic Cancer|Breast Cancer|Leukemia|Colorectal Cancer|Renal Cell Carcinoma|Cervical Cancer|Lymphoma|Kidney Cancer|Multiple Myeloma|Astrocytoma|Ovarian Cancer|Oligodendroglioma|Non-Small-Cell Lung Cancer|Gliosarcoma|Brain Cancer|Glioblastoma|Sarcoma|Glioma|Lymphocytic Chronic B-Cell Leukemia|Alveolar Soft Part Sarcoma|Chronic Lymphoid Leukemia|Chondrosarcoma|Endometrial Cancer|Melanoma|Lymphoma, B-Cell|Head and Neck Cancer|Gastrointestinal Stromal Tumors

Phase 1: Multiple Myeloma|Preleukemia|Acute Megakaryoblastic Leukemia|Acute Lymphoid Leukemia|Liver Cancer|Colorectal Cancer|Kidney Cancer|Chronic Myeloid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Monocytic Leukemia|Acute Promyelocytic Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic-Myeloproliferative Diseases|Diarrhea|Prostate Cancer|Renal Cell Carcinoma|Myelodysplastic Syndrome|Chronic Lymphoid Leukemia|Myeloproliferative Disorders|Myeloid, Accelerated Leukemia|Acute Myelomonocytic Leukemia|Adult T-Cell Leukemia-Lymphoma|Acute Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Erythroblastic Leukemia|Oncology Solid Tumor Unspecified|Blast Crisis|Hypokalemia|Angina, Unstable|Hypertrophy, Left Ventricular|Ovarian Cancer|Lymphoma|Neuroblastoma|Hepatitis C, Chronic|Hepatitis B, Chronic|Glioblastoma|Contraception|Surgical Wound Infection|Angina Pectoris|Heart Failure, Acute|Angina, Stable|Heart Failure, Chronic|Myocardial Infarction|Pregnancy Outcomes|HIV Infections|Torsades de Pointes|Brain Cancer|Neuromyelitis Optica|Astrocytoma|Oligodendroglioma

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
NCT00590954	P2	Completed	Glioma\|Brain Cancer	2019-11-11
NCI-2011-01409	P2	Completed	Oligodendroglioma\|Gliosarcoma\|Glioblastoma\|Astrocytoma	2018-11-16
AAAM3801	P1	Completed	Astrocytoma\|Glioblastoma\|Oligodendroglioma\|Brain Cancer	2017-10-27
NCT00776867	P1	Completed	Oncology Solid Tumor Unspecified	2017-07-01

Recent News Events

Date	Type	Title
03/01/2024	PubMed	Neuroprotective effects of Rehmannia glutinosa polysaccharide on chronic constant light (CCL)-induced oxidative stress and autophagic cell death via the AKT/mTOR pathway in mouse hippocampus and HT-22 cells.
02/01/2024	PubMed	Study on the mechanism of CXCL12/CXCR4-axis-mediated upregulation of IL-8 and IL-6 on the biological function of acute T lymphocyte leukaemia cells.
01/15/2024	PubMed	ROS/mtROS promotes TNTs formation via the PI3K/AKT/mTOR pathway to protect against mitochondrial damages in glial cells induced by engineered nanomaterials.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions